Abilify

Irritability, Schizophrenia, Agitation + 10 more

Treatment

1 FDA approval

20 Active Studies for Abilify

What is Abilify

Aripiprazole

The Generic name of this drug

Treatment Summary

Aripiprazole is a medication used to treat mental health conditions like schizophrenia, bipolar disorder, major depression, irritability in people with autism, and Tourette's syndrome. It can be taken orally or given as an injection to treat agitation related to schizophrenia or bipolar mania. Aripiprazole works by stimulating dopamine and serotonin receptors while inhibiting alpha-adrenergic and serotonin receptors. This drug was approved by the FDA in 2002.

Abilify

is the brand name

image of different drug pills on a surface

Abilify Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Abilify

Aripiprazole

2002

454

Approved as Treatment by the FDA

Aripiprazole, also known as Abilify, is approved by the FDA for 1 uses such as Schizophrenia .

Schizophrenia

Used to treat Schizophrenia in combination with Aripiprazole lauroxil

Effectiveness

How Abilify Affects Patients

Aripiprazole binds strongly to various receptors in the brain, such as those for serotonin, dopamine, and adrenaline. It also has weaker effects on other receptors. It is not yet known exactly how this binding of aripiprazole to these receptors results in its clinical effects.

How Abilify works in the body

Aripiprazole works to treat psychosis by activating dopamine and serotonin receptors. It may also cause unwanted side effects by affecting other receptors, such as the adrenergic alpha1 receptor, which can cause low blood pressure when standing.

When to interrupt dosage

The recommended dosage of Abilify is contingent upon the diagnosed condition, including Agitation, Schizophrenia and Alzheimer's Disease. The quantity of dosage is dependent on the mode of delivery noted in the table below.

Condition

Dosage

Administration

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Irritability

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Acute Coryza

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Psychotic Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Agitation

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Autism Spectrum Disorder (ASD)

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Tourette Syndrome

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Warnings

Abilify Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Aripiprazole may interact with Pulse Frequency

There are 20 known major drug interactions with Abilify.

Common Abilify Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aclidinium.

Alfuzosin

Major

Aripiprazole may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Aripiprazole may increase the antipsychotic activities of Amisulpride.

Aripiprazole lauroxil

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Abilify Toxicity & Overdose Risk

There have been no studies done on the safety and effectiveness of taking aripiprazole while pregnant. However, a national pregnancy registry is tracking mothers who take it while pregnant. Studies of other antipsychotic medications during pregnancy have found that babies are at risk of developing symptoms like muscle stiffness or withdrawal. Animal studies of aripiprazole have linked it to birth defects and fetal death at higher doses than the recommended for humans. Aripiprazole should only be prescribed if the benefits outweigh the risks. Babies exposed to the drug in the third trimester may develop symptoms like muscle stiffness or withdrawal that can last from hours to

image of a doctor in a lab doing drug, clinical research

Abilify Novel Uses: Which Conditions Have a Clinical Trial Featuring Abilify?

Currently, 469 active clinical trials are underway to ascertain the potential of Abilify in treating Alzheimer's Disease, Early Infantile Autism and Irritability.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Alzheimer's Disease

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Psychotic Depression

0 Actively Recruiting

Irritability

8 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Schizophrenia

31 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Autism Spectrum Disorder (ASD)

60 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1

Depression

213 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1

Tourette Syndrome

3 Actively Recruiting

Not Applicable

Abilify Reviews: What are patients saying about Abilify?

5

Patient Review

6/18/2022

Abilify for Additional Medications to Treat Depression

I've been on Trintellix for a few years now and, recently, I had been feeling very depressed and suicidal. However, my psychiatrist put me on Abilify and, after just three days, I'm virtually depression-free! This feels like a miracle to me; I haven't felt this good in years!

5

Patient Review

6/30/2022

Abilify for Bipolar I Disorder with Most Recent Episode Mixed

Abilify has worked very well for me over the last five years. It's important to remember that people react differently to medications, so what works for one person might not work for another.

4.7

Patient Review

9/15/2022

Abilify for Additional Medications to Treat Depression

This treatment has been working great for me. I have seen a significant reduction in my depression symptoms, which has had a positive impact on my quality of life. I have experienced some side effects, but they are manageable and haven't impacted my ability to live a normal life.

4.7

Patient Review

9/9/2022

Abilify for Additional Medications to Treat Depression

My kids think this is for schizophrenia. This is dangerous to translate because they are from broken homes and it's safe to say I am not any longer. It has several uses, but I use it for depression. Strong.

3.3

Patient Review

11/6/2022

Abilify for Additional Medications to Treat Depression

While this did an amazing job at stabilizing my mood, the side effects were just too much for me to handle. My anxiety increased significantly while taking this medication and made it hard to focus on anything else or go about my daily routine.

1

Patient Review

7/22/2022

Abilify for Additional Medications to Treat Depression

Do not under any circumstances take this drug. It completely ruined my life by causing me to gain an excessive amount of weight and develop a gambling addiction. The company who makes it, Bristol-Meyers, claims they did nothing wrong but I disagree.

1

Patient Review

9/1/2022

Abilify for Schizophrenia

ABILIFY is poison and caused me to become a compulsive gambler. It's completely useless and should be illegal. The company that manufactures it is scamming American taxpayers by making insurance companies pay outrageous prices for their drug.

1

Patient Review

9/16/2022

Abilify for Bipolar Disorder in Remission

As a child, I was prescribed this medication and it caused me to have uncontrollable muscle spasms in my jaw. My mouth was stuck shut and I came dangerously close to breaking my jaw. All the psychiatrist did was lower my dosage, but I was forced to take this for 2 years due to my age. Now, 18 years later, I suffer from chronic TMJ as a result of long-term side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about abilify

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Abilify used for?

"Aripiprazole is a medication that can be used to treat mental disorders such as bipolar I disorder, major depressive disorder, and schizophrenia. It can be used by itself or in combination with other medications."

Answered by AI

What are the negative side effects of Abilify?

"The following side effects may occur: dizziness, lightheadedness, drowsiness, nausea, vomiting, tiredness, excess saliva/drooling, blurred vision, weight gain, constipation, headache, and trouble sleeping. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

Is Abilify an antipsychotic or mood stabilizer?

"Abilify is an antipsychotic medication that affects chemicals in the brain to treat the symptoms of psychotic conditions like schizophrenia in adults and children aged 13 and up."

Answered by AI

Is Abilify an antipsychotic or antidepressant?

"The medicine Abilify is used to treat a variety of mental disorders, such as schizophrenia, bipolar disorder, Tourette syndrome, and irritability associated with autism. It can be used in combination with an antidepressant to treat depression."

Answered by AI

Clinical Trials for Abilify

Image of Training is all online and is available to participate in the study from anywhere in the US, run from a site in PA in Wexford, United States.

Emotional Intelligence Training for Autism

18+
All Sexes
Wexford, PA

Subjects are enrolled in pairs. Pairs consist of an autistic adult age 18-36 and a non-autistic learning partner who has a relationship with the autistic adult, such as a parent. The autistic adult in each pair receives the first stage of Kairon's online leadership training consisting of emotional literacy and healthy relationship topics. The learning partner in each pair receives Kairon's autism accommodation training while encouraging and providing feedback to their paired autistic adult. After training, both people in each pair evaluate the trainings' impacts on themselves and on their partner. Specifically, each autistic adult evaluates both the effectiveness of the leadership training they received and the effectiveness of the autism accommodation training that their paired learning partner received. Each learning partner evaluates both the effectiveness of the autism accommodation training they received and the effectiveness of the leadership training that their paired autistic adult received.

Recruiting
Has No Placebo

Training is all online and is available to participate in the study from anywhere in the US, run from a site in PA

Kairon Connect, PBC

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials
Image of UCLA Semel Institute in Los Angeles, United States.

Psilocybin-assisted CBT for Depression

21 - 60
All Sexes
Los Angeles, CA

The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT. Both treatment arms will receive two doses of psilocybin (10mg and then 25mg, separated by one month). In Phase II, participants will be randomized (1:1) to either a 12-session PA-CBT or a 6-session standard psilocybin-assisted therapy (PAT) condition (3 hours of preparation plus 3 hours of supportive therapy integration following the psilocybin experiences).

Phase 1 & 2
Recruiting

UCLA Semel Institute

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials
Image of University of Rochester Medical Center in Rochester, United States.

Deaf CBT-TS for Suicide Risk

18+
All Sexes
Rochester, NY

The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are: * Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors? * Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use? * Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress? * Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors. Participants will: * Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment. * Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months * Complete two follow-up assessments in 2 and 4 months.

Waitlist Available
Has No Placebo

University of Rochester Medical Center

Image of Sunwise Clinical Research /ID# 277555 in Walnut Creek, United States.

Icalcaprant for Depression

18 - 65
All Sexes
Walnut Creek, CA

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase 2
Recruiting

Sunwise Clinical Research /ID# 277555 (+12 Sites)

ABBVIE INC.

AbbVie

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials